Destabilization of Heterologous Proteins Mediated by the GSK3β Phosphorylation Domain of the β-Catenin Protein

Background and Aims: Wnt/β-catenin signaling plays important roles in development and cellular processes. The hallmark of canonical Wnt signaling activation is the stabilization of β-catenin protein in cytoplasm and/or nucleus. The stability of β-catenin is the key to its biological functions and is controlled by the phosphorylation of its amino-terminal degradation domain. Aberrant activation of β-catenin signaling has been implicated in the development of human cancers. It has been recently suggested that GSK3βmay play an essential role in regulating global protein turnover. Here, we investigate if the GSK3β phosphorylation site-containing degradation domain of β-catenin is sufficient to destabilize heterologous proteins. Methods and Results: We engineer chimeric proteins by fusing β-catenin degradation domain at the N- and/or C-termini of the enhanced green fluorescent protein (eGFP). In both transient and stable expression experiments, the chimeric GFP proteins exhibit a significantly decreased stability, which can be effectively antagonized by lithium and Wnt1. An activating mutation in the destruction domain significantly stabilizes the fusion protein. Furthermore, GSK3 inhibitor SB-216763 effectively increases the GFP signal of the fusion protein. Conversely, the inhibition of Wnt signaling with tankyrase inhibitor XAV939 results in a decrease in GFP signal of the fusion proteins, while these small molecules have no significant effects on the mutant destruction domain-GFP fusion protein. Conclusion: Our findings strongly suggest that the β-catenin degradation domain may be sufficient to destabilize heterologous proteins in Wnt signaling-dependent manner. It is conceivable that the chimeric GFP proteins may be used as a functional reporter to measure the dynamic status of β-catenin signaling, and to identify potential anticancer drugs that target β-catenin signaling.

[1]  T. He,et al.  Characterization of chondrocyte scaffold carriers for cell-based gene therapy in articular cartilage repair. , 2013, Journal of biomedical materials research. Part A.

[2]  W. Birchmeier,et al.  Wnt signaling in stem and cancer stem cells. , 2013, Current opinion in cell biology.

[3]  T. He,et al.  BMP9-regulated angiogenic signaling plays an important role in the osteogenic differentiation of mesenchymal progenitor cells , 2013, Journal of Cell Science.

[4]  T. He,et al.  Conditional immortalization establishes a repertoire of mouse melanocyte progenitors with distinct melanogenic differentiation potential. , 2012, The Journal of investigative dermatology.

[5]  T. He,et al.  Growth hormone synergizes with BMP9 in osteogenic differentiation by activating the JAK/STAT/IGF1 pathway in murine multilineage cells , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[7]  T. He,et al.  Conditionally Immortalized Mouse Embryonic Fibroblasts Retain Proliferative Activity without Compromising Multipotent Differentiation Potential , 2012, PloS one.

[8]  J. Qin,et al.  Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma , 2011, Oncogene.

[9]  T. He,et al.  Tetrandrine Inhibits Wnt/β-Catenin Signaling and Suppresses Tumor Growth of Human Colorectal Cancer , 2011, Molecular Pharmacology.

[10]  J. Plouhinec,et al.  Wnt Signaling Requires Sequestration of Glycogen Synthase Kinase 3 inside Multivesicular Endosomes , 2010, Cell.

[11]  T. He,et al.  Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma , 2010, Clinical Cancer Research.

[12]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[13]  T. He,et al.  Wnt antagonist SFRP3 inhibits the differentiation of mouse hepatic progenitor cells , 2009, Journal of cellular biochemistry.

[14]  T. He,et al.  BMP‐9‐induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/β‐catenin signalling , 2009, Journal of cellular and molecular medicine.

[15]  R. Nusse,et al.  Wnt signaling and stem cell control , 2008, Cell Research.

[16]  K. Kinzler,et al.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system , 2007, Nature Protocols.

[17]  T. He,et al.  Wnt signaling and human diseases: what are the therapeutic implications? , 2007, Laboratory Investigation.

[18]  A. Montag,et al.  CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem Cells , 2006, Molecular and Cellular Biology.

[19]  A. Montag,et al.  Connective Tissue Growth Factor (CTGF) Is Regulated by Wnt and Bone Morphogenetic Proteins Signaling in Osteoblast Differentiation of Mesenchymal Stem Cells* , 2004, Journal of Biological Chemistry.

[20]  Xi He,et al.  A Wnt-Wnt situation. , 2003, Developmental cell.

[21]  A. Montag,et al.  Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma , 2002, International journal of cancer.

[22]  Hongwei Cheng,et al.  Fluorescence-Based Functional Assay for Wnt/β-Catenin Signaling Activity , 2002 .

[23]  T. He,et al.  Tetracycline-regulated Gene Expression Mediated by a Novel Chimeric Repressor That Recruits Histone Deacetylases in Mammalian Cells* , 2001, The Journal of Biological Chemistry.

[24]  B. Alman,et al.  Suppressor of Fused Negatively Regulates β-Catenin Signaling* , 2001, The Journal of Biological Chemistry.

[25]  H Clevers,et al.  The chromatin remodelling factor Brg‐1 interacts with β‐catenin to promote target gene activation , 2001, The EMBO journal.

[26]  Chris Albanese,et al.  Negative regulation of the Wnt–β‐catenin pathway by the transcriptional repressor HBP1 , 2001, The EMBO journal.

[27]  Hui Zheng,et al.  Presenilin 1 Negatively Regulates β-Catenin/T Cell Factor/Lymphoid Enhancer Factor-1 Signaling Independently of β-Amyloid Precursor Protein and Notch Processing , 2001, The Journal of cell biology.

[28]  A. Fukui,et al.  Inhibition of the Wnt Signaling Pathway by Idax, a Novel Dvl-Binding Protein , 2001, Molecular and Cellular Biology.

[29]  Y. Konishi,et al.  Mutations of adenomatous polyposis coli and beta-catenin genes during progression of lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine in rats. , 2000, Cancer research.

[30]  T. Akiyama Wnt/beta-catenin signaling. , 2000, Cytokine & growth factor reviews.

[31]  A. Fukui,et al.  Inhibition of Wnt Signaling Pathway by a Novel Axin-binding Protein* , 2000, The Journal of Biological Chemistry.

[32]  A. Fukui,et al.  A Novel β-Catenin-binding Protein Inhibits β-Catenin-dependent Tcf Activation and Axis Formation* , 2000, The Journal of Biological Chemistry.

[33]  Hermann Bujard,et al.  Tetracycline-regulated gene expression in the brain , 2000, Current Opinion in Neurobiology.

[34]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[35]  P. Polakis Wnt signaling and cancer. , 2000, Genes & development.

[36]  T. Akiyama,et al.  Inhibition of Wnt signaling by ICAT, a novel β-catenin-interacting protein , 2000, Genes & Development.

[37]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[38]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[39]  M. Taketo,et al.  Intestinal polyposis in mice with a dominant stable mutation of the β‐catenin gene , 1999, The EMBO journal.

[40]  H Clevers,et al.  TCF transcription factors: molecular switches in carcinogenesis. , 1999, Biochimica et biophysica acta.

[41]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[42]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[44]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[45]  E. Fuchs,et al.  De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin , 1998, Cell.

[46]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[47]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[48]  R. Nusse,et al.  β-catenin: a key mediator of Wnt signaling , 1998 .

[49]  A. Levine,et al.  The role of beta‐catenin in cell adhesion, signal transduction, and cancer , 1998, Current opinion in oncology.

[50]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[51]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[52]  James R. Woodgett,et al.  Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells , 1996, Current Biology.

[53]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[54]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  F. Masiarz,et al.  Association of the APC gene product with beta-catenin. , 1993, Science.

[56]  K. Kinzler,et al.  Association of the APC tumor suppressor protein with catenins. , 1993, Science.

[57]  D. Benzeroual,et al.  [In Process Citation]. , 2015, Annales de cardiologie et d'angéiologie.

[58]  Jeff Davies Reproduced with the permission of Bird life Australia and , 2013 .

[59]  Q. Zhou,et al.  Fluorescence-based functional assay for Wnt/beta-catenin signaling activity. , 2002, BioTechniques.

[60]  B. Alman,et al.  Suppressor of fused negatively regulates beta-catenin signaling. , 2001, The Journal of biological chemistry.

[61]  A. Fukui,et al.  A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. , 2000, The Journal of biological chemistry.

[62]  T. Akiyama,et al.  Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. , 2000, Genes & development.

[63]  P. Morin,et al.  beta-catenin signaling and cancer. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[64]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[65]  K. Kinzler,et al.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. , 1999, Cell.

[66]  K Willert,et al.  Beta-catenin: a key mediator of Wnt signaling. , 1998, Current opinion in genetics & development.

[67]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.

[68]  Z. Paroush,et al.  Transcriptional repression by AML 1 and LEF-1 is mediated by the TLE y Groucho corepressors , 1998 .

[69]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Robbins,et al.  Stabilization of beta-catenin by genetic defects in melanoma cell lines. , 1997, Science.

[71]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.